by Sermonix Pharmaceuticals | Jun 12, 2024 | News
In preclinical mouse models, results suggested lasofoxifene could be an effective therapy for all hormone treatment-resistant breast tumors Phase 3 ELAINE-3 study is currently investigating lasofoxifene as a potential therapy for ESR1-mutated breast cancer COLUMBUS,...
by Sermonix Pharmaceuticals | Jun 6, 2024 | News
IND approval in China allows Shanghai Henlius Biotech, Sermonix’s Chinese development partner for oral lasofoxifene, to enroll ELAINE-3 trial patients in China Under strategic collaboration agreement signed in January, Henlius received exclusive rights from Sermonix...
Recent Comments